Replies to post #28557 on Ayala Pharmaceuticals Inc (fka ADXS)

[ignatiusrielly35]

Good luck with that. Clearly ADXS is not going out of its way to present prostate data at the conference that is not strong, whether it is mono or combo, or both. If only the mono is good, with not much synergy with Merck's checkpoint, then Merck should obviously still be interested in licensing PSA, because that means that its checkpoint provides little or no value to that indication. If the combo is better than the mono, same result. We only need one, but both would be ideal.

[Big Barnie]

raja

you have been hoping for bad data for a long time.

what do you think are your chances?

[Easymoneyman00]

Weird to me to think if it's not to good ? why even PR it? Why would you even bring it up unless it was sustainable improvement vs SOC? I'm all in this is a very long road to haul yet here I am on the road again chasing my dreams hoping ADXS shows a vast improvement over other therapies! If not then all is lost and we should run and hide our faces from this board never to return unless the give me my money back!